> > >

QuickCheck™

QuickCheck™ offers benefits verification. Download the form, then fax to NovoSecure™ at 1-866-488-6576 or email to mynovosecurespecialist@mynovosecure.com. Generally, a Summary of Benefits will be provided within 4 hours.a

aAvailable from 9:00 am to 4:00 pm ET.

Download

Preview

  • 0

Additional Information

We’ve created additional resources to address your questions:

Product Assistance Program Form

Register to get the latest updates about Esperoct®

Register to get the latest updates about Esperoct®

Register

Available from Novo Nordisk:

NovoSeven® RT coagulation factor VIIa (recombinant) logo

Visit website
Prescribing Information

Rebinyn® coagulation Factor IX (recombinant) GlycoPEGylated logo

Visit website
Prescribing Information

Novoeight® antihemophilic factor (recombinant) logo

Visit website
Prescribing Information

Tretten® coagulation factor XIII a-subunit (recombinant) logo

Visit website
Prescribing Information

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information